TFL Gallery / t-vitals-change
VST02 · Table
Summary of Vital Signs Change from Baseline at End of Treatment
The same measurements as a change from each subject's own observed Week 0 value.
- Slug
- t-vitals-change
- Regulatory ID
- VST02
- Type
- Table
- E3 position
- §14.3.5
- Status
- evidenced
- Current iteration
- v002
- Evidence
- 20/20 passing
- Requirements
- DSP-ALL-001 DSP-ALL-002 DSP-INTXT-001 DSP-INTXT-002 DSP-INTXT-003 DSP-VSC-001 DSP-VWC-001 DSP-VWC-002 STD-GATE-001 STD-GATE-002 STD-GATE-003 STD-GATE-004 STD-GATE-005 STD-MODEL-001 STD-MODEL-002 STD-MODEL-003 STD-MODEL-004 STD-MODEL-005 STD-SRC-001 STD-SRC-002
- Used in
- Clinical Study Report Table 14.3.5.2
- Post-Text Display Package Table 14.3.5.2
- Study model
- Safety Analysis Set SAFFL · grouped by TRT01P
- Specification
- 2 iterations
- Environment
- R 4.3.3 Darwin 23.6.0
- Bound by
- No text block binds it
- Values
- No value is sourced from it
- adsl254 rows · 70c7278
- advs32139 rows · ccc9f70
- analysis.yamlwhat to compute
- display.yamlhow to show it
- study modelSafety Analysis Set
- prepare_data()regenerate('t-vitals-change')
- build_ard()one row per statistic
- render_display()every variant
- render_rtf()the same cells
- ard.jsonv002 · 441 rows · 4a0f857
- table.htmlthe rendered display
- table.rtfsha256 ab3d8c9
- manifest.jsonwho, why, every hash
Generated by the same pipeline run that wrote the ARD and the HTML above, from the same rendered cells; the short hash is the manifest's record of the file.
| Summary of Vital Signs Change from Baseline at End of Treatment | |||
| Study CDISCPILOT01 — Safety Analysis Set | |||
| Placebo (N=86) | Xanomeline Low Dose (N=84) | Xanomeline High Dose (N=84) | |
|---|---|---|---|
| Systolic Blood Pressure (mmHg) | |||
| After lying down for 5 minutes | |||
| Week 24 | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| End of treatment | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| After standing for 1 minute | |||
| Week 24 | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| End of treatment | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| After standing for 3 minutes | |||
| Week 24 | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| End of treatment | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| Diastolic Blood Pressure (mmHg) | |||
| After lying down for 5 minutes | |||
| Week 24 | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| End of treatment | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| After standing for 1 minute | |||
| Week 24 | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| End of treatment | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| After standing for 3 minutes | |||
| Week 24 | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| End of treatment | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| Pulse (beats/min) | |||
| After lying down for 5 minutes | |||
| Week 24 | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| End of treatment | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| After standing for 1 minute | |||
| Week 24 | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| End of treatment | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| After standing for 3 minutes | |||
| Week 24 | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| End of treatment | |||
| n | |||
| Mean (SD) | |||
| Median | |||
| Min, Max | |||
| Treatment groups are PLANNED treatment (TRT01P). Twelve subjects in this study received a treatment other than the one they were randomised to; grouping by actual treatment (TRT01A) would give column sizes of 86, 96 and 72. | |||
| Blood pressure and pulse are measured in three positions and each position is summarised as its own series: a subject's baseline after standing for three minutes is not the baseline for their supine measurement. | |||
| End of treatment is the last observed measurement of that parameter in that position, at a planned visit after Week 0 up to and including Week 24. Unscheduled visits, the Week 26 follow-up visit and records derived by averaging or carry-forward are never selected. | |||
| Change from baseline is the subject's value minus that subject's own observed Week 0 value in the same position. A subject with no Week 0 measurement contributes to no row here, so n can be one below the corresponding n in the vital signs summary. | |||
| n is the number of subjects contributing a change; N in the column header is the number of subjects in the safety analysis set. | |||
| Source: advs, adsl (CDISCPILOT01 ADaM package, phuse-org/phuse-scripts). Data cut-off: 2014-07-01. | |||
| open.csr display t-vitals-change (post_text variant); generated from the committed ARD. | |||
Rendered from outputs/t-vitals-change/v002/table.html.
| analysis | group1 | group1_level | group2 | group2_level | variable | variable_level | context | stat_name | stat_label | warning | error | stat |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| population | TRT01P | Placebo | — | — | POPFL | Y | subject_count | n | n | — | — | 86 |
| population | TRT01P | Placebo | — | — | POPFL | Y | subject_count | N | N | — | — | 86 |
| population | TRT01P | Placebo | — | — | POPFL | Y | subject_count | p | % | — | — | 1 |
| population | TRT01P | Xanomeline Low Dose | — | — | POPFL | Y | subject_count | n | n | — | — | 84 |
| population | TRT01P | Xanomeline Low Dose | — | — | POPFL | Y | subject_count | N | N | — | — | 84 |
| population | TRT01P | Xanomeline Low Dose | — | — | POPFL | Y | subject_count | p | % | — | — | 1 |
| population | TRT01P | Xanomeline High Dose | — | — | POPFL | Y | subject_count | n | n | — | — | 84 |
| population | TRT01P | Xanomeline High Dose | — | — | POPFL | Y | subject_count | N | N | — | — | 84 |
| population | TRT01P | Xanomeline High Dose | — | — | POPFL | Y | subject_count | p | % | — | — | 1 |
| sbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | N | N | — | — | 58 |
| sbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | mean | Mean | — | — | -2.12068965517241 |
| sbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | sd | SD | — | — | 14.732798576713 |
| sbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | median | Median | — | — | -4 |
| sbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -10 |
| sbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 8 |
| sbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | min | Min | — | — | -28 |
| sbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | max | Max | — | — | 50 |
| sbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | N | N | — | — | 27 |
| sbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -0.259259259259259 |
| sbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 17.190320605129 |
| sbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | median | Median | — | — | 2 |
| sbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -8 |
| sbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 10 |
| sbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -48 |
| sbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 30 |
| sbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | N | N | — | — | 30 |
| sbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -5.6 |
| sbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 17.1797796140174 |
| sbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -7 |
| sbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -16 |
| sbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 8 |
| sbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -36 |
| sbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 26 |
| sbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | N | N | — | — | 83 |
| sbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | mean | Mean | — | — | -2.01204819277108 |
| sbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | sd | SD | — | — | 16.7619589459277 |
| sbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | median | Median | — | — | -4 |
| sbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -14 |
| sbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 8 |
| sbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | min | Min | — | — | -32 |
| sbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | max | Max | — | — | 50 |
| sbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | N | N | — | — | 84 |
| sbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -3.13095238095238 |
| sbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 16.5716987385736 |
| sbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -2 |
| sbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -13 |
| sbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 10 |
| sbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -48 |
| sbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 34 |
| sbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | N | N | — | — | 82 |
| sbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -5.80487804878048 |
| sbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 14.4764082445874 |
| sbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -8 |
| sbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -15 |
| sbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 5 |
| sbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -36 |
| sbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 29 |
| sbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | N | N | — | — | 58 |
| sbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | mean | Mean | — | — | -1.68965517241379 |
| sbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | sd | SD | — | — | 16.8712429440009 |
| sbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | median | Median | — | — | 0 |
| sbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -14 |
| sbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 10 |
| sbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | min | Min | — | — | -32 |
| sbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | max | Max | — | — | 40 |
| sbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | N | N | — | — | 27 |
| sbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -0.148148148148148 |
| sbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 17.7280822506243 |
| sbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -1 |
| sbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -11 |
| sbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 10 |
| sbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -30 |
| sbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 48 |
| sbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | N | N | — | — | 30 |
| sbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -6.33333333333333 |
| sbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 19.4906402529846 |
| sbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -9 |
| sbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -20 |
| sbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 4 |
| sbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -36 |
| sbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 42 |
| sbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | N | N | — | — | 83 |
| sbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | mean | Mean | — | — | -1.63855421686747 |
| sbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | sd | SD | — | — | 17.7589402515981 |
| sbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | median | Median | — | — | 0 |
| sbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -12 |
| sbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 10 |
| sbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | min | Min | — | — | -46 |
| sbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | max | Max | — | — | 48 |
| sbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | N | N | — | — | 84 |
| sbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -2.78571428571429 |
| sbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 17.3982906157794 |
| sbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -1.5 |
| sbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -12 |
| sbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 7 |
| sbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -52 |
| sbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 48 |
| sbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | N | N | — | — | 82 |
| sbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -6.65853658536586 |
| sbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 16.9779955717525 |
| sbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -8 |
| sbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -20 |
| sbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 4 |
| sbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -44 |
| sbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 42 |
| sbp_stand3_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | N | N | — | — | 58 |
| sbp_stand3_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | mean | Mean | — | — | -0.982758620689655 |
| sbp_stand3_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | sd | SD | — | — | 15.8030547561199 |
| sbp_stand3_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | median | Median | — | — | -3.5 |
| sbp_stand3_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -12 |
| sbp_stand3_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 7 |
| sbp_stand3_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | min | Min | — | — | -36 |
| sbp_stand3_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | max | Max | — | — | 38 |
| sbp_stand3_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | N | N | — | — | 27 |
| sbp_stand3_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -0.148148148148148 |
| sbp_stand3_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 16.2047089635264 |
| sbp_stand3_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | median | Median | — | — | 0 |
| sbp_stand3_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -10 |
| sbp_stand3_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 10 |
| sbp_stand3_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -30 |
| sbp_stand3_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 30 |
| sbp_stand3_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | N | N | — | — | 30 |
| sbp_stand3_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -8.96666666666667 |
| sbp_stand3_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 16.8839514359629 |
| sbp_stand3_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -8 |
| sbp_stand3_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -20 |
| sbp_stand3_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 1 |
| sbp_stand3_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -40 |
| sbp_stand3_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 30 |
| sbp_stand3_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | N | N | — | — | 83 |
| sbp_stand3_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | mean | Mean | — | — | -2.53012048192771 |
| sbp_stand3_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | sd | SD | — | — | 16.6054188550353 |
| sbp_stand3_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | median | Median | — | — | -4 |
| sbp_stand3_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -12 |
| sbp_stand3_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 6 |
| sbp_stand3_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | min | Min | — | — | -40 |
| sbp_stand3_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | max | Max | — | — | 48 |
| sbp_stand3_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | N | N | — | — | 83 |
| sbp_stand3_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -3.49397590361446 |
| sbp_stand3_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 16.5126510952825 |
| sbp_stand3_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -4 |
| sbp_stand3_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -12 |
| sbp_stand3_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 4 |
| sbp_stand3_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -52 |
| sbp_stand3_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 60 |
| sbp_stand3_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | N | N | — | — | 81 |
| sbp_stand3_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -8.25925925925926 |
| sbp_stand3_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 15.2108331278876 |
| sbp_stand3_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -8 |
| sbp_stand3_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -20 |
| sbp_stand3_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 2 |
| sbp_stand3_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -40 |
| sbp_stand3_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 30 |
| dbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | N | N | — | — | 58 |
| dbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | mean | Mean | — | — | -0.793103448275862 |
| dbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | sd | SD | — | — | 10.8203165318192 |
| dbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | median | Median | — | — | -0.5 |
| dbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -10 |
| dbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 4 |
| dbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | min | Min | — | — | -18 |
| dbp_lying_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | max | Max | — | — | 41 |
| dbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | N | N | — | — | 27 |
| dbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -0.888888888888889 |
| dbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 7.71279323508542 |
| dbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -2 |
| dbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -6 |
| dbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 4 |
| dbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -20 |
| dbp_lying_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 16 |
| dbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | N | N | — | — | 30 |
| dbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -2.16666666666667 |
| dbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 9.20301050194177 |
| dbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -1 |
| dbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -8 |
| dbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 2 |
| dbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -20 |
| dbp_lying_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 21 |
| dbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | N | N | — | — | 83 |
| dbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | mean | Mean | — | — | -0.975903614457831 |
| dbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | sd | SD | — | — | 10.9866614290443 |
| dbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | median | Median | — | — | 0 |
| dbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -10 |
| dbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 4 |
| dbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | min | Min | — | — | -34 |
| dbp_lying_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | max | Max | — | — | 41 |
| dbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | N | N | — | — | 84 |
| dbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -2.01190476190476 |
| dbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 8.8037424238513 |
| dbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -2 |
| dbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -6.5 |
| dbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 4 |
| dbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -30 |
| dbp_lying_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 18 |
| dbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | N | N | — | — | 82 |
| dbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -3.09756097560976 |
| dbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 8.79479329145637 |
| dbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -4 |
| dbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -9 |
| dbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 2 |
| dbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -24 |
| dbp_lying_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 21 |
| dbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | N | N | — | — | 58 |
| dbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | mean | Mean | — | — | -2.25862068965517 |
| dbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | sd | SD | — | — | 10.0813538926942 |
| dbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | median | Median | — | — | -4 |
| dbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -10 |
| dbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 4 |
| dbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | min | Min | — | — | -23 |
| dbp_stand1_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | max | Max | — | — | 24 |
| dbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | N | N | — | — | 27 |
| dbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | 1 |
| dbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 7.29594197007962 |
| dbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | median | Median | — | — | 2 |
| dbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -2 |
| dbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 6 |
| dbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -20 |
| dbp_stand1_wk24 | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 18 |
| dbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | N | N | — | — | 30 |
| dbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -2.33333333333333 |
| dbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 10.8511347994936 |
| dbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -7 |
| dbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -10 |
| dbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 8 |
| dbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -18 |
| dbp_stand1_wk24 | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 22 |
| dbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | N | N | — | — | 83 |
| dbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | mean | Mean | — | — | -2.83132530120482 |
| dbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | sd | SD | — | — | 10.1738776897772 |
| dbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | median | Median | — | — | -2 |
| dbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -10 |
| dbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 4 |
| dbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | min | Min | — | — | -34 |
| dbp_stand1_eot | TRT01P | Placebo | — | — | CHGBL | — | continuous | max | Max | — | — | 24 |
| dbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | N | N | — | — | 84 |
| dbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -1.21428571428571 |
| dbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 8.93493404965032 |
| dbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | median | Median | — | — | 0 |
| dbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -6 |
| dbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 4 |
| dbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -30 |
| dbp_stand1_eot | TRT01P | Xanomeline Low Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 20 |
| dbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | N | N | — | — | 82 |
| dbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | mean | Mean | — | — | -2.10975609756098 |
| dbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | sd | SD | — | — | 12.1004092345458 |
| dbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | median | Median | — | — | -2 |
| dbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p25 | Q1 | — | — | -10 |
| dbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | p75 | Q3 | — | — | 4 |
| dbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | min | Min | — | — | -34 |
| dbp_stand1_eot | TRT01P | Xanomeline High Dose | — | — | CHGBL | — | continuous | max | Max | — | — | 28 |
| dbp_stand3_wk24 | TRT01P | Placebo | — | — | CHGBL | — | continuous | N | N | — | — | 58 |
Showing the first 250 of 441 rows — the full ARD is committed beside the display.
- Schema
- opencsr/ard/v1
- Generated
- 2026-09-02T15:19:44Z
- Spec hash
- sha256:0d204e9c533b1d93eb583c63b8aa9eac5db5b6c58b7ea53e4609d472abbd2f6b
- Display hash
- sha256:840b2267d026eae3d7fa9464b214d236dfd35bcc8aa28392ce97b2848e748b75
- ARD file
- outputs/t-vitals-change/v002/ard.json
- ARD hash
- sha256:4a0f857568b5e33975c88570e4525d0215eefa7c318e011fbb57561d966d2c75
Source datasets
| Dataset | Rows | Package | Hash |
|---|---|---|---|
| adsl | 254 | phuse-org/phuse-scripts:data/adam 398a6d33ced9359ffb58c46650a6d488811176b1 | sha256:70c7278e83e571a7d4a94fd864c98bf8ca243c7c2cc9eec8b99a40fa7bc98e35 |
| advs | 32139 | phuse-org/phuse-scripts:data/adam 398a6d33ced9359ffb58c46650a6d488811176b1 | sha256:ccc9f70e768c4c6529f31714c501e606c2edb69e8096da6cf4157785d428fcb0 |
Environment
R 4.3.3 · Darwin 23.6.0 · cards 0.6.1 · cardx 0.2.5 · gtsummary 2.3.0 · gt 1.0.0 · dplyr 1.1.4 · pharmaverseadam 1.1.0 · jsonlite 2.0.0 · yaml 2.3.10 · digest 0.6.37
# ------------------------------------------------------------------------------
# t-vitals-change — Summary of Vital Signs Change from Baseline at End of Treatment
# ------------------------------------------------------------------------------
# Target: Table 14-7.02 of the CDISCPILOT01 clinical study report (27 June 2006).
#
# Eighteen summaries: three measures (systolic and diastolic blood pressure,
# pulse) x three positions x two post-baseline time points. Each is its own `analyses` entry
# because v0 supports one grouping variable, which the treatment column uses;
# measure, position and visit are therefore selection, not grouping, and each
# combination gets an addressable name of its own (`sbp_lying_bl`, ...).
#
# The reference table puts treatment in the rows and n / Mean / SD / Median /
# Min / Max in the columns. This one transposes that: treatment is the column, as
# it is everywhere else in this library, and the six statistics become four rows
# under a Measure -> Position -> Visit heading stack. The statistics are the same
# statistics; only the axis they are laid out on differs.
#
# CHGBL is the subject's value minus that subject's own observed Week 0 value in
# the same position, derived in prepare_data(). A subject with no Week 0
# measurement has no change and is absent from every row here, which is why the
# n on a change row can be one below the n on the matching value row in t-vitals.
#
# Temperature, height, BMI, body surface area and mean arterial pressure are
# collected in ADVS and are NOT summarised here: the reference report's vital
# signs display covers blood pressure and pulse only, and Section 12.5 of its
# narrative says so.
# ------------------------------------------------------------------------------
id: t-vitals-change
title: "Summary of Vital Signs Change from Baseline at End of Treatment"
regulatory_id: VST02
type: table
dataset: advs
analysis_set: safety
denominator: adsl
group:
- TRT01P
total: false
analyses:
# Supplies the column denominators (N = subjects in the safety analysis set).
# Every other analysis here reports n, the number of subjects contributing a
# measurement at that visit, which is smaller and means something different.
- name: population
method: subject_count
label: "Subjects in the safety analysis set"
variable: POPFL
- name: sbp_lying_wk24
method: continuous
label: "Systolic Blood Pressure (mmHg) — After lying down for 5 minutes — Week 24"
variables: [CHGBL]
filter: 'PARAMCD == "SYSBP" & ATPT == "AFTER LYING DOWN FOR 5 MINUTES" & AVISIT == "Week 24" & is.na(DTYPE) & !is.na(CHGBL)'
- name: sbp_lying_eot
method: continuous
label: "Systolic Blood Pressure (mmHg) — After lying down for 5 minutes — End of treatment"
variables: [CHGBL]
filter: 'PARAMCD == "SYSBP" & ATPT == "AFTER LYING DOWN FOR 5 MINUTES" & EOTFL == "Y" & !is.na(CHGBL)'
- name: sbp_stand1_wk24
method: continuous
label: "Systolic Blood Pressure (mmHg) — After standing for 1 minute — Week 24"
variables: [CHGBL]
filter: 'PARAMCD == "SYSBP" & ATPT == "AFTER STANDING FOR 1 MINUTE" & AVISIT == "Week 24" & is.na(DTYPE) & !is.na(CHGBL)'
- name: sbp_stand1_eot
method: continuous
label: "Systolic Blood Pressure (mmHg) — After standing for 1 minute — End of treatment"
variables: [CHGBL]
filter: 'PARAMCD == "SYSBP" & ATPT == "AFTER STANDING FOR 1 MINUTE" & EOTFL == "Y" & !is.na(CHGBL)'
- name: sbp_stand3_wk24
method: continuous
label: "Systolic Blood Pressure (mmHg) — After standing for 3 minutes — Week 24"
variables: [CHGBL]
filter: 'PARAMCD == "SYSBP" & ATPT == "AFTER STANDING FOR 3 MINUTES" & AVISIT == "Week 24" & is.na(DTYPE) & !is.na(CHGBL)'
- name: sbp_stand3_eot
method: continuous
label: "Systolic Blood Pressure (mmHg) — After standing for 3 minutes — End of treatment"
variables: [CHGBL]
filter: 'PARAMCD == "SYSBP" & ATPT == "AFTER STANDING FOR 3 MINUTES" & EOTFL == "Y" & !is.na(CHGBL)'
- name: dbp_lying_wk24
method: continuous
label: "Diastolic Blood Pressure (mmHg) — After lying down for 5 minutes — Week 24"
variables: [CHGBL]
filter: 'PARAMCD == "DIABP" & ATPT == "AFTER LYING DOWN FOR 5 MINUTES" & AVISIT == "Week 24" & is.na(DTYPE) & !is.na(CHGBL)'
- name: dbp_lying_eot
method: continuous
label: "Diastolic Blood Pressure (mmHg) — After lying down for 5 minutes — End of treatment"
variables: [CHGBL]
filter: 'PARAMCD == "DIABP" & ATPT == "AFTER LYING DOWN FOR 5 MINUTES" & EOTFL == "Y" & !is.na(CHGBL)'
- name: dbp_stand1_wk24
method: continuous
label: "Diastolic Blood Pressure (mmHg) — After standing for 1 minute — Week 24"
variables: [CHGBL]
filter: 'PARAMCD == "DIABP" & ATPT == "AFTER STANDING FOR 1 MINUTE" & AVISIT == "Week 24" & is.na(DTYPE) & !is.na(CHGBL)'
- name: dbp_stand1_eot
method: continuous
label: "Diastolic Blood Pressure (mmHg) — After standing for 1 minute — End of treatment"
variables: [CHGBL]
filter: 'PARAMCD == "DIABP" & ATPT == "AFTER STANDING FOR 1 MINUTE" & EOTFL == "Y" & !is.na(CHGBL)'
- name: dbp_stand3_wk24
method: continuous
label: "Diastolic Blood Pressure (mmHg) — After standing for 3 minutes — Week 24"
variables: [CHGBL]
filter: 'PARAMCD == "DIABP" & ATPT == "AFTER STANDING FOR 3 MINUTES" & AVISIT == "Week 24" & is.na(DTYPE) & !is.na(CHGBL)'
- name: dbp_stand3_eot
method: continuous
label: "Diastolic Blood Pressure (mmHg) — After standing for 3 minutes — End of treatment"
variables: [CHGBL]
filter: 'PARAMCD == "DIABP" & ATPT == "AFTER STANDING FOR 3 MINUTES" & EOTFL == "Y" & !is.na(CHGBL)'
- name: pulse_lying_wk24
method: continuous
label: "Pulse (beats/min) — After lying down for 5 minutes — Week 24"
variables: [CHGBL]
filter: 'PARAMCD == "PULSE" & ATPT == "AFTER LYING DOWN FOR 5 MINUTES" & AVISIT == "Week 24" & is.na(DTYPE) & !is.na(CHGBL)'
- name: pulse_lying_eot
method: continuous
label: "Pulse (beats/min) — After lying down for 5 minutes — End of treatment"
variables: [CHGBL]
filter: 'PARAMCD == "PULSE" & ATPT == "AFTER LYING DOWN FOR 5 MINUTES" & EOTFL == "Y" & !is.na(CHGBL)'
- name: pulse_stand1_wk24
method: continuous
label: "Pulse (beats/min) — After standing for 1 minute — Week 24"
variables: [CHGBL]
filter: 'PARAMCD == "PULSE" & ATPT == "AFTER STANDING FOR 1 MINUTE" & AVISIT == "Week 24" & is.na(DTYPE) & !is.na(CHGBL)'
- name: pulse_stand1_eot
method: continuous
label: "Pulse (beats/min) — After standing for 1 minute — End of treatment"
variables: [CHGBL]
filter: 'PARAMCD == "PULSE" & ATPT == "AFTER STANDING FOR 1 MINUTE" & EOTFL == "Y" & !is.na(CHGBL)'
- name: pulse_stand3_wk24
method: continuous
label: "Pulse (beats/min) — After standing for 3 minutes — Week 24"
variables: [CHGBL]
filter: 'PARAMCD == "PULSE" & ATPT == "AFTER STANDING FOR 3 MINUTES" & AVISIT == "Week 24" & is.na(DTYPE) & !is.na(CHGBL)'
- name: pulse_stand3_eot
method: continuous
label: "Pulse (beats/min) — After standing for 3 minutes — End of treatment"
variables: [CHGBL]
filter: 'PARAMCD == "PULSE" & ATPT == "AFTER STANDING FOR 3 MINUTES" & EOTFL == "Y" & !is.na(CHGBL)'
id: t-vitals-change
title: "Summary of Vital Signs Change from Baseline at End of Treatment"
study: CDISCPILOT01
population_label: "Safety Analysis Set"
cutoff: "2014-07-01"
source: "Source: advs, adsl (CDISCPILOT01 ADaM package, phuse-org/phuse-scripts). Data cut-off: 2014-07-01."
footnotes:
- "Treatment groups are PLANNED treatment (TRT01P). Twelve subjects in this study received a treatment other than the one they were randomised to; grouping by actual treatment (TRT01A) would give column sizes of 86, 96 and 72."
- "Blood pressure and pulse are measured in three positions and each position is summarised as its own series: a subject's baseline after standing for three minutes is not the baseline for their supine measurement."
- "End of treatment is the last observed measurement of that parameter in that position, at a planned visit after Week 0 up to and including Week 24. Unscheduled visits, the Week 26 follow-up visit and records derived by averaging or carry-forward are never selected."
- "Change from baseline is the subject's value minus that subject's own observed Week 0 value in the same position. A subject with no Week 0 measurement contributes to no row here, so n can be one below the corresponding n in the vital signs summary."
- "n is the number of subjects contributing a change; N in the column header is the number of subjects in the safety analysis set."
columns:
order: [Placebo, "Xanomeline Low Dose", "Xanomeline High Dose"]
format:
digits:
# `N:` and `n:` are deliberately absent. R's YAML reader resolves BOTH bare
# `N` and bare `n` to the boolean FALSE, so declaring the two together is a
# duplicate-key parse error and declaring either alone silently keys the digit
# plan under "FALSE". Counts default to zero decimals, which is what is wanted.
p: 1
mean: 1
sd: 2
median: 1
min: 1
max: 1
rows:
- { label: "Systolic Blood Pressure (mmHg)", section: true }
- { label: "After lying down for 5 minutes", section: true, indent: 1 }
- { label: "Week 24", section: true, indent: 2 }
- { analysis: sbp_lying_wk24, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: sbp_lying_wk24, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: sbp_lying_wk24, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: sbp_lying_wk24, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "End of treatment", section: true, indent: 2 }
- { analysis: sbp_lying_eot, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: sbp_lying_eot, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: sbp_lying_eot, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: sbp_lying_eot, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "After standing for 1 minute", section: true, indent: 1 }
- { label: "Week 24", section: true, indent: 2 }
- { analysis: sbp_stand1_wk24, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: sbp_stand1_wk24, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: sbp_stand1_wk24, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: sbp_stand1_wk24, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "End of treatment", section: true, indent: 2 }
- { analysis: sbp_stand1_eot, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: sbp_stand1_eot, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: sbp_stand1_eot, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: sbp_stand1_eot, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "After standing for 3 minutes", section: true, indent: 1 }
- { label: "Week 24", section: true, indent: 2 }
- { analysis: sbp_stand3_wk24, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: sbp_stand3_wk24, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: sbp_stand3_wk24, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: sbp_stand3_wk24, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "End of treatment", section: true, indent: 2 }
- { analysis: sbp_stand3_eot, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: sbp_stand3_eot, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: sbp_stand3_eot, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: sbp_stand3_eot, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "Diastolic Blood Pressure (mmHg)", section: true }
- { label: "After lying down for 5 minutes", section: true, indent: 1 }
- { label: "Week 24", section: true, indent: 2 }
- { analysis: dbp_lying_wk24, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: dbp_lying_wk24, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: dbp_lying_wk24, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: dbp_lying_wk24, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "End of treatment", section: true, indent: 2 }
- { analysis: dbp_lying_eot, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: dbp_lying_eot, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: dbp_lying_eot, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: dbp_lying_eot, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "After standing for 1 minute", section: true, indent: 1 }
- { label: "Week 24", section: true, indent: 2 }
- { analysis: dbp_stand1_wk24, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: dbp_stand1_wk24, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: dbp_stand1_wk24, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: dbp_stand1_wk24, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "End of treatment", section: true, indent: 2 }
- { analysis: dbp_stand1_eot, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: dbp_stand1_eot, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: dbp_stand1_eot, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: dbp_stand1_eot, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "After standing for 3 minutes", section: true, indent: 1 }
- { label: "Week 24", section: true, indent: 2 }
- { analysis: dbp_stand3_wk24, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: dbp_stand3_wk24, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: dbp_stand3_wk24, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: dbp_stand3_wk24, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "End of treatment", section: true, indent: 2 }
- { analysis: dbp_stand3_eot, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: dbp_stand3_eot, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: dbp_stand3_eot, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: dbp_stand3_eot, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "Pulse (beats/min)", section: true }
- { label: "After lying down for 5 minutes", section: true, indent: 1 }
- { label: "Week 24", section: true, indent: 2 }
- { analysis: pulse_lying_wk24, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: pulse_lying_wk24, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: pulse_lying_wk24, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: pulse_lying_wk24, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "End of treatment", section: true, indent: 2 }
- { analysis: pulse_lying_eot, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: pulse_lying_eot, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: pulse_lying_eot, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: pulse_lying_eot, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "After standing for 1 minute", section: true, indent: 1 }
- { label: "Week 24", section: true, indent: 2 }
- { analysis: pulse_stand1_wk24, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: pulse_stand1_wk24, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: pulse_stand1_wk24, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: pulse_stand1_wk24, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "End of treatment", section: true, indent: 2 }
- { analysis: pulse_stand1_eot, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: pulse_stand1_eot, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: pulse_stand1_eot, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: pulse_stand1_eot, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "After standing for 3 minutes", section: true, indent: 1 }
- { label: "Week 24", section: true, indent: 2 }
- { analysis: pulse_stand3_wk24, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: pulse_stand3_wk24, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: pulse_stand3_wk24, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: pulse_stand3_wk24, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
- { label: "End of treatment", section: true, indent: 2 }
- { analysis: pulse_stand3_eot, variable: CHGBL, pattern: "{N}", label: "n", indent: 3 }
- { analysis: pulse_stand3_eot, variable: CHGBL, pattern: mean_sd, label: "Mean (SD)", indent: 3 }
- { analysis: pulse_stand3_eot, variable: CHGBL, pattern: median, label: "Median", indent: 3 }
- { analysis: pulse_stand3_eot, variable: CHGBL, pattern: range, label: "Min, Max", indent: 3 }
variants:
post_text: {}
v002current
One study (D0032 R2, #60): read the CDISC pilot own ADaM package, which assigns every subject the arm the rest of the report uses. Spec unchanged; lane changed.
2026-09-02T15:19:44Z · @obotclaw
v001
Initial generation of VST02, targeting Table 14-7.02 of the reference clinical study report for this study.
2026-08-27T04:06:03Z · @jwildfire
Every iteration is kept: outputs/t-vitals-change/vNNN/ holds the spec snapshot, the ARD, the rendered output, and a manifest recording who regenerated it, why, and from which commit.